Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

8/24/2015

0 Comments

 
Plainsboro Township, NJ - According to John Carroll, "Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs--and this time the Danish biotech company will not be focused on another cancer pact. The deal starts small, seeded with a $2 million upfront that looks quite similar to other deals Genmab has struck with a slate of Big Pharma companies over the years. Going after two undisclosed targets--neither of which are cancer-related--Genmab can earn up to $500 million in milestones if Novo ultimately chooses to keep an exclusive license on what it gets for both programs, or $400 million if it chooses to go the nonexclusive route.
While the two partners are staying quiet about their focus aside from ruling out any cancer applications, Novo has a carefully calibrated pipeline that's closely focused on diabetes and obesity with more work underway on hemophilia and growth disorders.
Genmab and Novartis ($NVS) had developed R&D ties even before GlaxoSmithKline ($GSK) transferred the oncology rights to ofatumumab to Novartis in a big asset flip. That drug is now marketed as Arzerra in search of an ever-expanding cancer market. Genmab remains partnered with GSK on ofatumumab as an autoimmune drug, with a program in multiple sclerosis alongside other late-stage initiatives. And Genmab and its partner J&J have been making rapid progress with daratumumab for multiple myeloma--with a rolling submission headed to the FDA in what analysts hope will turn into a blockbuster with $4 billion peak sales--while Seattle Genetics focused on an outlicensing pact around solid cancers.
Last fall Genmab handed over an $11 million up front and promising up to $200 million more to get the right to use Seattle Genetics' antibody-drug conjugate technology for its HuMax-AXL program. The program uses an antibody targeted at AXL, with Seattle Genetics' ($SGEN) widely deployed "armed antibody" tech helping with the payload delivery.
Like Johnson & Johnson ($JNJ), Novo is interested specifically in Genmab's DuoBody platform for developing bispecific antibodies that can grapple with two different targets.
"Today's agreement with Novo Nordisk is an example of how we can leverage access to our unique state-of-the art antibody expertise and collaborations to generate diverse revenue streams in areas beyond cancer," said Jan van de Winkel, the CEO of Genmab, in a statement.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619